Current NPS threats volume III. by unknown










UNODC Early Warning Advisory Toxicology Highlights
Figure 1: UNODC Early Warning Advisory NPS Portal database














The information highlights a dynamic NPS market. Overall, 
stimulants account for the largest group of substances 
reported, followed by synthetic cannabinoid receptor agonists 
(SCRAs) and classic hallucinogens. In recent years, reports 
of substances in most groups have either plateaued or even 
decreased following an initial rapid increase from 2012-2015. 
However, certain groups of NPS such as synthetic opioid 
receptor agonists continue to be on the rise with an almost four 
fold increase from 2016 until mid-2020. The group of sedative/
hypnotics has also shown a steady increase in recent years.
NPS	toxicology	case	reports
Over the period from January 2019 to April 2020, 670 toxicology 
cases involving 46 individual NPS were reported to UNODC. Of 
these cases, 62% were classified as driving under the influence 
of drugs (DUID), 26% post-mortem (PM), 4% clinical admissions 
and 8% were cases grouped as “other” (e.g. drug facilitated 
sexual assault) (Figure 3). 
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Trend	analysis	of	NPS	reported	by	Member	States
Currently, approximately 1004 individual NPS have been 
reported to the UNODC EWA by 125 countries and territories. 
These substances can be classified into six groups based on 
their mode of action and the number of reports of substances 
within each of these groups from 2009 to 2020 is shown below. 
What	is	the	UNODC	Early	Warning	Advisory	(EWA)?
In 2013, the United Nations Office on Drugs and Crime 
(UNODC) established the Early Warning Advisory (EWA) on New 
Psychoactive Substances (NPS) in response to the Commission 
on Narcotic Drugs (CND) Resolution 56/4 (2013) entitled 
“Enhancing international cooperation in the identification and 
reporting of new psychoactive substances”. The EWA serves 
as a tool for effective, evidence-based policy responses by 
monitoring, analysing and reporting global and regional trends 
on NPS. The UNODC EWA is a voluntary online data system that 
consolidates regular and ad hoc submissions from forensic drug 
testing and toxicology laboratories, Member States and partner 
organisations on NPS found in seized materials and toxicology 
cases. 
Since 2018, the EWA has enhanced its features by including 
toxicology data in order to identify the NPS which pose 
the greatest threat to public health, thus, assisting in the 
prioritisation of substances assessed for international control 
as well as legislative responses at the national level. 
The following report represents a snapshot analysis of the most 
recent cases submitted from toxicology laboratories within 13 
Member States between January 2019 and April 2020. The 
reporting countries arise from geographical regions which 
include North America, Europe, Asia and Oceania. Although the 
analysis allows for a broader understanding of the associated 
harm of NPS, it is not an exhaustive representation of the 



















































*Note: 2020 data not finalised
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In volume II of Current NPS Threats published in January 2020 
(https://www.unodc.org/unodc/en/scientists/current-nps 
-threats.html) toxicology case reports received by UNODC 
showed the growing importance of benzodiazepine-type 
NPS with sedative/hypnotic effects. This increasing trend has 
continued well into 2020 with sedatives/hypnotics accounting 
for the largest group (68%) of NPS in toxicology reports, 
followed by SCRAs, plant-based substances in particular kratom 
and synthetic opioids (Figure 4).
Benzodiazepines	in	toxicology	cases
As of July 2020, 34 individual sedative/hypnotic substances 
have been reported by 49 countries and territories, of which 
29 are benzodiazepine-type NPS and 5 are derivatives of the 
CNS depressant methaqualone. Between 2019 and April 
2020, a total of 10 individual benzodiazepine-type NPS were 
identified in toxicology cases reported to UNODC with etizolam, 
flualprazolam and flubromazolam accounting for 64% of all 
identified NPS*. Their individual distribution across toxicology 
case types is shown in Figure 5.
Benzodiazepines are widely used in medicine as anticonvulsants, 
sedatives and tranquilizers and there are a total of 38 substances 
in this class under international control following the recent 
placement of phenazepam (2016), etizolam and flualprazolam 
(both in March 2020) in Schedule IV of the 1971 Convention on 
Psychotropic Substances**. Benzodiazepines, both legitimate 
medicines and benzodiazepine-type NPS, are often detected 
in drug overdose cases and can contribute to serious adverse 
health effects and death, particularly in combination with 
opioids.
A large proportion (83%, N=402) of DUID cases identified the 
presence of benzodiazepine-type NPS, with flualprazolam and 
flubromazolam representing the two most reported NPS at 51% 
and 22% respectively. 
*Note: Case reports were predominately recorded in the United States with 
some cases also reported in Canada, Australia, Finland, Sweden and Switzerland.
**Note: International control of etizolam and flualprazolam comes into force 
on November 3, 2020. Flubromazolam will be subject to critical review at the 
43rd Expert Committee of Drug Dependence of the World Health Organisation 
in October 2020.
Benzodiazepine-type NPS were also identified in 48% of 
PM cases (N=197). In case reports, etizolam, flualprazolam, 
flubromazolam and phenazepam were assessed to have either 
contributed to or been the cause of death in 48% of PM cases 
within this category (N=111), clearly indicating their potential 
to cause harm. Additionally, etizolam and flubromazolam, 
both with two cases each, have been causal to death in the 
absence of any other substance identified (e.g. controlled 
drug, medicines or alcohol). Yet, the fact that (fatal) overdoses 
involving benzodiazepine-type NPS are typically poly-substance 
cases adds complexity in understanding their potential to cause 
harm
The proportion of cases involving the three most frequently 
reported NPS (etizolam, flualprazolam, and flubromazolam) 
that were categorized as poly-drug use was generally very high, 
between 80-90%. In particular, controlled substances, such 
as cannabis, but also medicines were frequently identified in 
addition to NPS. The proportion of cases in which more than 
one NPS was identified was between 10% and 16% and mainly 
involved a combination of these three substances. 
When possible, blood concentration ranges of these 
benzodiazepine-type NPS were determined and reported. In 
fatal cases, these ranged between 12.0 and 80.0 ng/mL  (cardiac 
blood, n=5) for etizolam, between 100 and 500 ng/mL  (femoral 
blood, n=5) for flualprazolam, 37.0 and 130 ng/mL  (cardiac 
blood, n=2) for flubromazolam and between 10.0 and 119 ng/
mL  (femoral blood, n=2) for phenazepam. 
For some comparison, in DUID cases the reported peripheral 
blood concentrations were between 2.50 and 373 ng/mL 
(n=23) and between 5.50 and 26.0 ng/mL  (n=4), for etizolam 
and flualprazolam respectively. Blood concentrations of 
phenazepam in non-fatal cases were reported between 30.0 
and 47.7 ng/mL  (n=2). There is a notable overlap between 
concentrations in fatal and non-fatal cases involving etizolam 
and phenazepam, which is not uncommon in toxicology and 
could be attributed to a number of factors; e.g. tolerance in 
long-term users.
The analysis presented here reveals that benzodiazepine-
type NPS can play an important role in contributing to serious 
harm, either alone or in combination with other psychoactive 
substances. Thus, forensic laboratories should ensure that 
they have appropriate analytical methods available for their 

































DUID Post-mortem Clinical Admissions Other case type
3
Poly-drug	use	across	different	case	types
Poly-drug use was identified as an important consideration in 
cases associated with the use of NPS in previous volumes of 
Current NPS Threats and the latest information shows that this 
continues to occur across all types of toxicology cases. Overall, 
poly-drug use was identified in 81% of all toxicology cases 
reviewed (N=670), with a similar proportion in the 171 post-
mortem cases analysed. In about half of the cases, at least one 
controlled substance such as methamphetamine or cocaine 
were identified, while medicines as well as alcohol were present 
in 82% of post-mortem cases. The proportion of post-mortem 
cases in which more than one NPS was identified was 19%.
In DUID cases, poly-drug use seems to be even more widespread, 
with a combination of substances used in over 90% of DUID 
cases. Controlled substances were found in 81% of these cases 
and 51% were found to have consumed medicines, mostly 
prescription benzodiazepines and opioids. In 13% of cases the 
driver was under the influence of multiple NPS.
Isotonitazene,	Kratom	and	Brorphine
Cases featuring Isotonitazene 
NPS with opioid-like effects, continue to emerge on illicit drug 
markets. One recent example is isotonitazene, a synthetic 
opioid that has emerged in Europe and North America and 
until recently had not appeared in any toxicology cases. Since 
June 2019 however, eight instances of fatalities associated 
with isotonitazene have been reported to UNODC from the 
United States. Furthermore, in all but one case, the substance 
was assessed to have been causal to the death of the 
individual. Reported blood concentrations ranged between 
0.4 and 4.40 ng/mL (n=8). However, due to its novelty and 
opioid-like effects which might be misinterpreted as heroin 
overdoses, it is possible that many cases remain undetected 
to this day. Isotonitazene will be subject to critical review by 
the 43rd Expert Committee on Drug Dependence (ECDD). 
Increasing reports of fatalities involving Kratom
Recently, another NPS that has shown its potential to cause 
serious harm, including fatalities, is Kratom, a plant material 
derived from the tropical evergreen tree Mitragyna speciosa. 
The leaves contain pharmacologically active alkaloids especially 
mitragynine and 7-hydroxymitragynyine, which show opioid as 
well as stimulant effects. Cases involving Kratom were evenly 
split between DUID and PM cases, with 90% of all Kratom 
cases involving the concomitant use of other substances. In 
the previous volume of Current NPS Threats, Kratom cases 
accounted for 46% of all NPS detected in fatalities. Nevertheless, 
there had not been a single case reported in which Kratom was 
causal to the outcome. However, since July 2019, at least 14 
cases have been identified where Kratom was deemed causal 
(n=7) or contributory (n=7) to the fatality. Of the seven causal 
PM cases, two where labelled single drug use cases. In fatal 
PM cases where blood concentrations had been determined, 
cardiac mitragynine concentrations of between 113 and 4280 
ng/mL  (n=5)  were reported. For comparison, analysed blood 
mitragynine concentrations in DUID cases were  between 10.7 
and 333 ng/mL  (n=24).
	
Brorphine - a new synthetic opioid
First reported to the UNODC EWA in July 2019, Brorphine 
((1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-
2H-benzo[d]imidazol-2-one), a piperidine benzimidazolone 
classified as a synthetic opioid, started to make its way onto the 
NPS market in Canada and the United States.  More recently, 
in June/July 2020 this substance was found during seven post-
mortem cases in the USA and once during a clinical admission 
in Belgium. An initial study1 on the patient showed that the 
substance appeared to have a long half-life and high potency 
compared to medicinal opioids such as hydromorphone. 
Toxicologial screening of serum samples of the patient using 
immunoassay and enzymatic methods gave a negative result 
highlighting one of the main challenges faced by toxicologists 
when analysing and identifying new and emerging substances. 
1 Verougstraete, N., Vandeputte, M., Lyphout, C., Cannaert, A., Hulpia, F., 
Van Calenbergh, S., Verstraete, A., Stove, C., Journal of Analytical Toxicology, 















Features of the UNODC Early Warning Advisory on New Psychoactive Substances














*Note: The boundaries and names shown and the designations in this document do not imply official endorsement or acceptance by the United Nations. Dashed 
lines represent undetermined boundaries. The dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. 
The final status of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Republic of Sudan and the Republic of South 
Sudan has not yet been determined. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland 
concerning sovereignty over the Falkland Islands (Malvinas).
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